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Abstract In Japan, the Research Committee on Intrac-
table Vasculitides, supported by the Ministry of Health,
Labour and Welfare, has been promoting basic and clinical
research on vasculitis since 1972. The present Research
Committee on Intractable Vasculitides comprises 4 sub-
committees under the direction of a Principal Investigator:
Basic and Pathological Research Subcommittee, Clinical
Research Subcommittee of Small and Medium-sized Ves-
sel Vasculitis, Clinical Research Subcommittee of Large-
sized Vessel Vasculitis, and International Cooperation
Research Subcommittee. Since 2008, 9 nationwide clinical
studies for vasculitis have been conducted and 8 clinical
and basic studies are in progress.
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The Research Committee on Intractable Vasculitides,
the Ministry of Health, Labour and Welfare of Japan
The Research Committee on Intractable Vasculitides, sup-
ported by the Ministry of Health, Labour and Welfare of
Japan, has conducted and promoted basic and clinical
research on vasculitis since 1972. We study 9 diseases:
Takayasu arteritis, temporal arteritis, polyarteritis nodosa,
Buerger disease, microscopic polyangiitis, granulomatosis
with polyangiitis, eosinophilic granulomatosis with polyan-
giitis, antiphospholipid syndrome, and rheumatoid vasculitis.
Experts from several fields including nephrology, rheuma-
tology, pulmonology, dermatology, cardiology, vascular
surgery, pathology, epidemiology, and otorhinolaryngology
work cooperatively. The present Research Committee on
Intractable Vasculitides comprises 4 subcommittees under the
direction of a Principal Investigator (Hirofumi Makino):Basic
and Pathological Research Subcommittee of Vasculitis Syn-
drome (Yasunori Okada), Clinical Research Subcommittee of
Small and Medium-sized Vessel Vasculitis Syndrome (Yo-
shihiro Arimura), Clinical Research Subcommittee of Large-
sized Vessel Vasculitis Syndrome (Kazuo Tanemoto), and
International Cooperation Research Subcommittee of Vas-
culitis Syndrome (Kazuo Suzuki, Shoichi Fujimoto) (Fig. 1).
Since 2008, we have conducted a retrospective cohort study
elucidating risk factors associated with relapse in microscopic
polyangiitis (MPA) patients [1] and a nationwide epidemiol-
ogic study of eosinophilic granulomatosis with polyangiitis.
The clinical studies described below are in progress currently.
RemIT-JAV
To describe the current treatment status and evaluate the
effectiveness of these treatments for Japanese patients with
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all types of antineutrophil cytoplasmic antibodies (ANCA)-
associated vasculitides (AAV), we conducted a nationwide
prospective cohort study of remission induction therapy in
Japanese patients with AAV (RemIT-JAV). Twenty-two
university hospitals and referring hospitals participated in this
study; consecutive patients newly diagnosed with AAV were
enrolled from April 2009 to December 2010. The criteria of
primary systemic vasculitis proposed by the European Med-
icines Agency (EMEA) algorithm was employed for enroll-
ment [2]. This study was registered on the University Hospital
Medical Information Network Clinical Trials Registry
(UMIN000001648). Patients were evaluated at 3, 6, 12, 18,
and 24 months and at relapse. The primary outcome measure
was remission rate, and secondary outcome measures were
survival rate, renal survival rate, and relapse. In total, 156
AAV patients were enrolled; all observations were completed
by March 2013. Final data collection is in progress.
Co-RemIT-JAV
Based on our retrospective study elucidating the risk
factors for relapse in patients with myeloperoxidase
(MPO)-ANCA positive MPA [1], we are conducting an
observational cohort study of remission maintenance
therapy in Japanese AAV patients (Co-RemIT-JAV)
(UMIN000006373). The study objective is to clarify the
safety and efficacy of remission maintenance therapy in
Japanese AAV patients. At present, 60 of 156 AAV
patients registered in RemIT-JAV were extended to follow
up every 6 months up to 48 months after the end of fol-
low-up for RemIT-JAV. The primary outcome measure is
relapse rate, and secondary outcome measures are survival
and renal survival rates. The observation stage will be
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Fig. 1 Overview of the tasks of the Research Committee on
Intractable Vasculitides. CRF case report form, ANCA antineutrophil
cytoplasmic antibody, AAV ANCA-associated vasculitis, DCVAS
Diagnostic and Classification Criteria in Vasculitis Study, PEXIVAS
plasma exchange and glucocorticoid dosing in the treatment of
ANCA-associated vasculitides, RemIT-JAV-RPGN prospective cohort
study of remission induction therapy in Japanese patients with
ANCA-associated vasculitides and rapidly progressive glomerulone-
phritis, Co-RemIT-JAV observational cohort study of remission
maintenance therapy in Japanese patients with ANCA-associated
vasculitis, RemIT-JAV prospective cohort study of remission induc-
tion therapy in Japanese patients with ANCA-associated vasculitides
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RemIT-JAV-RPGN
After RemIT-JAV, we conducted a nationwide, prospective
cohort study of remission induction therapy in Japanese
patients with ANCA-associated vasculitides and rapidly
progressive glomerulonephritis (RemIT-JAV-RPGN)
(UMIN000005136) including 47 university hospitals and
referring hospitals. Enrollment of consecutive patients
newly diagnosed with AAV began in April 2011 and will
continue till December 2013. The primary and some sec-
ondary outcome measures are the same as those in RemIT-
JAV, but pathological analysis of renal involvement and
radiological analysis of pulmonary involvement will be
added. Further, biological samples (serum, urine, and total
RNA) will be collected and offered to the Basic and
Pathological Research Subcommittee for Research for
identifying candidate biomarkers.
Prospective cohort study for large-sized vessel vasculitis
We also conducted a nationwide Japanese prospective
observational study on the current state and efficacy of
therapeutics for large-vessel vasculitis (UMIN000010414).
The subjects included patients newly diagnosed with
Takayasu arteritis and giant cell arteritis. The study
objective was to clarify the current state and efficacy of
therapeutics for large-vessel vasculitis in Japan and to
evaluate the utility of the current diagnostic criteria and
classification for large-vessel vasculitis. The primary out-
come measure of this study is remission rate. The study
began in November 2012, and patients will be registered
until March 2014. Final follow-up will be completed in
March 2016.
Other research
The International Cooperation Research Subcommittee is
leading the effort to join some international collaborative
clinical research studies: the Diagnostic and Classification
Criteria in Vasculitis Study (DCVAS) (NCT01066208), the
Plasma Exchange and Glucocorticoid Dosing in the
Treatment of ANCA-Associated Vasculitis (PEXIVAS)
Study (NCT00987389), and a comparison study of phe-
notype and outcome in microscopic polyangiitis between
Europe and Japan.
A genome-wide association study in AAV patients
registered in the Japanese clinical studies RemIT-JAV and
RemIT-JAV-RPGN, and a prospective study of the sever-
ity-based treatment protocol for Japanese patients with
MPO-ANCA-associated vasculitis (JMAAV) [3], is also in
progress.
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